NASDAQ: ASLNAslan Pharmaceuticals Ltd Stock
$0.47+0.00 (+0%)
Updated Apr 24, 2024
ASLN Price
$0.47
Fair Value Price
$0.03
Market Cap
$8.27M
52 Week Low
$0.39
52 Week High
$4.69
P/E
-0.17x
P/B
-0.62x
P/S
0.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.00M
Earnings
-$44.22M
Gross Margin
100%
Operating Margin
-331.29%
Profit Margin
-368.5%
Debt to Equity
-2.85
Operating Cash Flow
-$43M
Beta
0.78
Next Earnings
Apr 26, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ASLN Overview
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASLN ($0.47) is overvalued by 1,260.69% relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ASLN ($0.47) is not significantly undervalued (1,260.69%) relative to our estimate of its Fair Value price of $0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASLN due diligence checks available for Premium users.
Be the first to know about important ASLN news, forecast changes, insider trades & much more!
ASLN News
Valuation
ASLN fair value
Fair Value of ASLN stock based on Discounted Cash Flow (DCF)
Price
$0.47
Fair Value
$0.03
Overvalued by
1,260.69%
ASLN ($0.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASLN ($0.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
15.69x
Market
41.27x
ASLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.62x
Industry
5.86x
ASLN's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.5M
Profit Margin
0%
ASLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ASLN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$24.6M
Liabilities
$37.9M
Debt to equity
-2.85
ASLN's short-term assets ($24.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASLN's long-term liabilities ($24.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ASLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASLN vs Biotech Stocks
Aslan Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.